The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses.

By B. Carreno, M. Collins. Annual Review of Immunology, 2002

981 citations recorded by the source corpus.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/e8621c6d38ebc7e4b5cd1d594edbb5f0def4db7c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. D. Pardoll
2. R. Parry
3. Craig B. Thompson
4. H. Yagita
5. T. Gajewski
6. Kenneth A. Frauwirth
7. M. Azuma
8. C. Blank

In Oncology

1. D. Pardoll
2. Craig B. Thompson
3. T. Gajewski
4. M. Azuma
5. C. Blank
6. J. Bluestone
7. Antoni Ribas
8. Lieping Chen

Citations in the corpus

• The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice (2003, background): “Termination of an immune response is achieved through a number of different mechanisms (1) including regulatory costimulatory molecules (2).”
• PD-1/PD-L1 pathway: current researches in cancer. (2020, neutral): “lar to induced T-cell co-stimulator [9].”
• CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms (2004, background): “Our results appear to be inconsistent with previous reports demonstrating that, in mice, CTLA-4 deficiency results in a more pronounced autoimmune phenotype than PD-1 deficiency (10, 27).”
• Homozygous loss of ICOS is associated with adult-onset common variable immunodeficiency (2003, background): “A central molecule involved in T cell costimulation is CD2”
• Expression of Programmed Death 1 Ligands by Murine T Cells and APC1 (2002, background): “Structurally, PD-1 belongs to the CD28/CTLA-4 subfamily of the Ig superfamily and contains a single Ig V-like domain in its extracellular region (5, 6).”
• CD28 costimulation: from mechanism to therapy (2016, background): “These receptors consist of paired V-set immunoglobulin superfamily (IgSF) domains attached to single transmembrane domains and cytoplasmic domains that contain critical signaling motifs (Carreno and Collins, 2002).”
• Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy (2005, background): “Besides the well-described B7-1/B7-2/CD28/CTLA-4 pathway, a growing number of B7 family ligands and their receptors have been identified that have been shown to modulate TCR signals [10, 11].”
• B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 Expression (2004, background): “like motifs that may recruit phosphatases, similar to other negative regulators (7, 10).”